SBIR/STTR Research Award

SBIR Phase II: A Perfusable, Revascularized, Cardiac-Derived Patch for the Treatment of Heart Disease

Award identifier eb057f81d3c113ea4c9bf48f7950f2a9e75c79d6382bcb71f9a4b182a5b28592Awarding agency National Science Foundation

Award amount

$500,000

Program and phase

SBIR · Phase II

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Miromatrix Medical Inc.
Proposal award date
2013-08-01
Contract end date
2015-07-31
UEI
FRFCJNBVB911
Solicitation number
Not reported
Topic code
BC

Research abstract

This Small Business Innovations Research Phase (SBIR) II project is to support the continued development of using proprietary perfusion decellularization technology to create a fully revascularized cardiac patch for the treatment of ischemic heart disease and congenital heart repair. Current surgical approaches for cardiac reconstruction utilize synthetic materials that do not have the ability to grow and remodel with the patient. Feasibility will be demonstrated by in-vitro and in-vivo characterization to create a perfusable cardiac-derived revascularized cardiac patch to promote faster reconstruction of functional tissue by providing a fully perfusable scaffold with a composition and architecture similar to native cardiac tissue. This product will have significant advantages over existing technologies, including: 1) full thickness, biological, cardiac-derived matrix material; 2) vascular supply to support migrating cells and remodeling; 3) superior mechanical properties; and, 4) no need for immunosuppressive therapies. Moreover, this will be the first cardiac-derived, revascularized patch available for treating ischemic areas of the heart. The broader impact/commercial potential of this project, if successful, is the development of a revascularized cardiac patch to treat ischemic heart failure and congenital repair in a way that is superior to existing technologies. While medical advancements have decreased the overall mortality rate for acute myocardial infarction patients, therapeutic options are lacking to address the underlying loss of myocardial tissue, resulting in a mortality rate greater than 33% at five years. Inhibiting the onset or delaying the severity of heart failure will have a significant effect on lowering this mortality rate and reducing the treatment cost of heart failure, which currently is estimated at over $37 billion annually. The use of this product will further enhance the medical and scientific understanding of the mechanisms by which damaged cardiac tissue may be restored/repaired and patient life may be extended following myocardial infarction.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

3 SBIR/STTR records share this UEI (2012–2019). Reported award amounts total $2,647,489. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: National Science Foundation, Department of Health and Human Services

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.